Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PiC-D in Double Refractory Multiple Myeloma
NCT02542657Phase 2Completed
- Start
- Oct 2015
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clarithromycin, dexamethasone, ixazomib and pomalidomide in multiple myeloma (MM). Primary endpoints: Maximum Tolerated Dose at 14 months and Complete Response and Stringent Complete Response at 7 years. Started Oct 2015; status: completed.
02
Drugs
clarithromycindexamethasoneixazomibpomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02542657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02542657.